These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16552506)

  • 1. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose.
    Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Lainscak M; Mrhar A; Breskvar K; Dolzan V
    Eur J Clin Pharmacol; 2006 Apr; 62(4):291-6. PubMed ID: 16552506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
    Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
    Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
    Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP
    Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
    Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy.
    Naganuma M; Shiga T; Nishikata K; Tsuchiya T; Kasanuki H; Fujii E
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):363-7. PubMed ID: 11907638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study.
    Gemmati D; Burini F; Talarico A; Fabbri M; Bertocco C; Vigliano M; Moratelli S; Cuneo A; Serino ML; Avato FM; Tisato V; Gaudio RM
    PLoS One; 2016; 11(9):e0162084. PubMed ID: 27606428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
    Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
    Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of simvastatin on warfarin disposition and dose requirements.
    Sconce EA; Khan TI; Daly AK; Wynne HA; Kamali F
    J Thromb Haemost; 2006 Jun; 4(6):1422-4. PubMed ID: 16706996
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients].
    Siguret V; Gouin I; Golmard JL; Geoffroy S; Andreux JP; Pautas E
    Rev Med Interne; 2004 Apr; 25(4):271-4. PubMed ID: 15050794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
    Perini JA; Struchiner CJ; Silva-Assunção E; Santana IS; Rangel F; Ojopi EB; Dias-Neto E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Dec; 84(6):722-8. PubMed ID: 18754001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.
    Bryk A; Wypasek E; Awsiuk M; Maj D; Undas A
    Cardiovasc Drugs Ther; 2015 Jun; 29(3):257-64. PubMed ID: 25986145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
    Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
    Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.
    O'Brien TJ; Kidd RS; Richard CA; Ha NH; Witcher P; Tran LV; Barbour A; Tuck M; McIntosh SD; Douglas JN; Harralson AF
    Clin Chim Acta; 2013 Sep; 424():73-5. PubMed ID: 23688605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.